Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niclosamide - First Wave BioPharma

Next Previous
Drug Profile

Niclosamide - First Wave BioPharma

Alternative Names: FW 424; FW-1022; FW-420; FW-CD; FW-COV; FW-ICI-AC; FW-UC; FW-UP; micronized niclosamide - First Wave Biopharma

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator First Wave Bio
  • Developer First Wave Bio; First Wave BioPharma
  • Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; NF-kappa B inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ulcerative proctitis; Ulcerative proctosigmoiditis
  • Preclinical Crohn's disease; Gastroenteritis; Ulcerative colitis
  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 31 Dec 2023 First Wave Biopharma has patent protection for niclosamide in COVID-19 gastrointestinal infections in USA and Patent Cooperation Treaty (PCT) (First Wave BioPharma SEC 2024)
  • 27 Dec 2023 Undisclosed company enters into non-binding term sheet agreement to acquire Niclosamide from First Wave Biopharma
  • 25 Apr 2023 First Wave BioPharma has patents pending for compositions and methods for treating conditions characterized by an abnormal inflammatory response in the US prior to April 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top